EA200900706A1 - Арилвинилазациклоалкановые соединения и способы их получения и применения - Google Patents

Арилвинилазациклоалкановые соединения и способы их получения и применения

Info

Publication number
EA200900706A1
EA200900706A1 EA200900706A EA200900706A EA200900706A1 EA 200900706 A1 EA200900706 A1 EA 200900706A1 EA 200900706 A EA200900706 A EA 200900706A EA 200900706 A EA200900706 A EA 200900706A EA 200900706 A1 EA200900706 A1 EA 200900706A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
compounds
disease
treatment
central nervous
Prior art date
Application number
EA200900706A
Other languages
English (en)
Other versions
EA019240B1 (ru
Inventor
Джеффри Дэниел Шмитт
Гари Морис Далл
Ариель Женевуа-Борелла
Марк Капе
Мишель Шев
Original Assignee
Таргасепт Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Таргасепт Инк. filed Critical Таргасепт Инк.
Publication of EA200900706A1 publication Critical patent/EA200900706A1/ru
Publication of EA019240B1 publication Critical patent/EA019240B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Описываются новые винилазациклоалкановые соединения формулы (I). Соединения представляют лиганды различных nAChR. Соединения и их фармацевтически приемлемые соли могут применяться для приготовления фармацевтических композиций и/или медикаментов, предназначенных для профилактики или лечения расстройств, связанных с дисфункцией nAChR, в частности, в центральной нервной системе или желудочно-кишечной системе. Примеры типов расстройств, которые могут лечиться, включают нейродегенеративные расстройства, включая расстройства центральной нервной системы, такие как болезнь Альцгеймера, когнитивные расстройства, двигательные расстройства, такие как болезнь Паркинсона, лекарственная зависимость, нарушения поведения, и воспалительные расстройства в желудочно-кишечной системе. Соединения также могут служить в качестве анальгетиков при лечении острой, хронической или рецидивной боли.
EA200900706A 2003-03-05 2004-03-04 Арилвинилазациклоалкановые соединения и способы их получения и применения EA019240B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (2)

Publication Number Publication Date
EA200900706A1 true EA200900706A1 (ru) 2009-10-30
EA019240B1 EA019240B1 (ru) 2014-02-28

Family

ID=32926772

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200501425A EA010870B1 (ru) 2003-03-05 2004-03-04 Арилвинилазациклоалкановые соединения и способы их получения и применения
EA200900706A EA019240B1 (ru) 2003-03-05 2004-03-04 Арилвинилазациклоалкановые соединения и способы их получения и применения
EA200801764A EA014714B1 (ru) 2003-03-05 2004-03-04 Арилвинилазациклоалкановое соединение, фармацевтическая композиция на его основе и способы его применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200501425A EA010870B1 (ru) 2003-03-05 2004-03-04 Арилвинилазациклоалкановые соединения и способы их получения и применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200801764A EA014714B1 (ru) 2003-03-05 2004-03-04 Арилвинилазациклоалкановое соединение, фармацевтическая композиция на его основе и способы его применения

Country Status (32)

Country Link
US (8) US7098331B2 (ru)
EP (3) EP1947100B1 (ru)
JP (3) JP4663627B2 (ru)
KR (4) KR101018083B1 (ru)
CN (3) CN101255155A (ru)
AR (3) AR043469A1 (ru)
AT (3) ATE496046T1 (ru)
AU (3) AU2004217903B2 (ru)
BR (1) BRPI0409576A (ru)
CA (1) CA2516514C (ru)
CL (1) CL2004000452A1 (ru)
CY (2) CY1110391T1 (ru)
DE (2) DE602004031165D1 (ru)
DK (2) DK1601670T3 (ru)
EA (3) EA010870B1 (ru)
ES (3) ES2309507T3 (ru)
GT (1) GT200400033A (ru)
HK (3) HK1084949A1 (ru)
IL (3) IL170155A (ru)
JO (1) JO2488B1 (ru)
MX (1) MXPA05009386A (ru)
NO (3) NO331920B1 (ru)
NZ (1) NZ541795A (ru)
PA (1) PA8597201A1 (ru)
PE (1) PE20040930A1 (ru)
PL (5) PL394600A1 (ru)
PT (2) PT2085395E (ru)
SI (2) SI2085395T1 (ru)
TW (3) TWI377204B (ru)
UY (1) UY28218A1 (ru)
WO (1) WO2004078752A1 (ru)
ZA (1) ZA200506790B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
WO2009140201A1 (en) * 2008-05-12 2009-11-19 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
PL3279195T3 (pl) * 2008-12-01 2020-12-14 Oyster Point Pharma, Inc. Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
BRPI1014247A2 (pt) * 2009-06-17 2016-04-12 Targacept Inc reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.
SG181109A1 (en) 2009-12-07 2012-07-30 Targacept Inc 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
US20130237550A1 (en) * 2010-03-11 2013-09-12 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
WO2017177024A1 (en) 2016-04-07 2017-10-12 Oyster Point Pharma, Inc. Methods of treating ocular conditions
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
TW202019417A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
SK285198B6 (sk) 1997-10-27 2006-08-03 Neurosearch A/S Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie
AU5326100A (en) 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2381252A1 (en) 1999-09-14 2001-03-22 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
WO2001032264A1 (en) 1999-11-01 2001-05-10 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2003008559A2 (en) 2001-07-19 2003-01-30 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
ATE394394T1 (de) 2008-05-15
US20100010042A1 (en) 2010-01-14
ES2385941T3 (es) 2012-08-03
UY28218A1 (es) 2005-06-30
EA010870B1 (ru) 2008-12-30
US20150164894A1 (en) 2015-06-18
US8063068B2 (en) 2011-11-22
MXPA05009386A (es) 2005-11-04
EP1947100B1 (en) 2011-07-27
TW200927746A (en) 2009-07-01
KR20090021228A (ko) 2009-02-27
GT200400033A (es) 2005-05-29
AU2008258188A1 (en) 2009-01-15
SI2085395T1 (sl) 2011-05-31
DE602004031165D1 (de) 2011-03-03
US20110152293A1 (en) 2011-06-23
AR070570A2 (es) 2010-04-21
PL1601670T3 (pl) 2008-10-31
ATE517893T1 (de) 2011-08-15
HK1116800A1 (en) 2009-01-02
EP1601670B1 (en) 2008-05-07
IL197889A (en) 2013-03-24
AR043469A1 (es) 2005-07-27
PA8597201A1 (es) 2004-09-28
EP2085395A1 (en) 2009-08-05
EP2085395B1 (en) 2011-01-19
KR20120014236A (ko) 2012-02-16
PL394604A1 (pl) 2011-07-18
ES2389106T3 (es) 2012-10-23
NZ541795A (en) 2008-03-28
PL215059B1 (pl) 2013-10-31
NO20054120L (no) 2005-10-03
TW200505909A (en) 2005-02-16
JO2488B1 (en) 2009-10-05
HK1084949A1 (en) 2006-08-11
JP2009292825A (ja) 2009-12-17
PL394600A1 (pl) 2011-07-18
EA014714B1 (ru) 2011-02-28
EP1601670A1 (en) 2005-12-07
CL2004000452A1 (es) 2005-05-20
BRPI0409576A (pt) 2006-04-18
KR101185541B1 (ko) 2012-09-24
ZA200506790B (en) 2006-05-31
CA2516514A1 (en) 2004-09-16
KR20090021227A (ko) 2009-02-27
US20140107164A1 (en) 2014-04-17
AU2008258187B2 (en) 2010-08-05
KR20060006006A (ko) 2006-01-18
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
CN101550132A (zh) 2009-10-07
EP1947100A1 (en) 2008-07-23
NO20091888L (no) 2005-10-03
JP4663627B2 (ja) 2011-04-06
NO20054120D0 (no) 2005-09-05
AU2008258188B2 (en) 2011-02-24
TWI339662B (en) 2011-04-01
EA019240B1 (ru) 2014-02-28
DK1601670T3 (da) 2008-08-25
US7098331B2 (en) 2006-08-29
NO20092231L (no) 2005-10-03
ATE496046T1 (de) 2011-02-15
AU2008258187A1 (en) 2009-01-15
KR100953150B1 (ko) 2010-04-19
PT2085395E (pt) 2011-04-20
US20100267776A1 (en) 2010-10-21
PE20040930A1 (es) 2005-02-18
CY1111615T1 (el) 2015-10-07
US20040176348A1 (en) 2004-09-09
PL216979B1 (pl) 2014-06-30
PL2085395T3 (pl) 2011-05-31
NO332293B1 (no) 2012-08-20
SI1601670T1 (sl) 2008-10-31
IL197890A (en) 2013-11-28
JP2006519868A (ja) 2006-08-31
TW200927745A (en) 2009-07-01
PL378415A1 (pl) 2006-04-03
JP5537085B2 (ja) 2014-07-02
EA200801764A1 (ru) 2008-12-30
CN100526308C (zh) 2009-08-12
DE602004013553D1 (de) 2008-06-19
AU2004217903A1 (en) 2004-09-16
US20080293778A1 (en) 2008-11-27
ES2309507T3 (es) 2008-12-16
PT1601670E (pt) 2008-07-11
CN1756754A (zh) 2006-04-05
DK2085395T3 (da) 2011-04-18
KR101018083B1 (ko) 2011-03-02
EA200501425A1 (ru) 2006-02-24
US8633222B2 (en) 2014-01-21
HK1130254A1 (en) 2009-12-24
TWI377204B (en) 2012-11-21
CA2516514C (en) 2012-02-07
CN101550132B (zh) 2012-03-28
AU2004217903B2 (en) 2010-03-04
JP5537084B2 (ja) 2014-07-02
US7714001B2 (en) 2010-05-11
US8067443B2 (en) 2011-11-29
NO331920B1 (no) 2012-04-30
IL170155A (en) 2013-08-29
US20060094732A1 (en) 2006-05-04
JP2010001296A (ja) 2010-01-07
WO2004078752A1 (en) 2004-09-16
CN101255155A (zh) 2008-09-03

Similar Documents

Publication Publication Date Title
IL197890A (en) Arylvinylchloroalkylan compounds and their preparation methods and uses
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
WO2001060826A3 (en) SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO2004110387A3 (en) Sigma ligands for neuronal regeneration and functional recovery
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
TW200502221A (en) Novel lactams and uses thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
ATE451368T1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
TW200728300A (en) Therapeutic agents
WO2007053580A3 (en) Sigma ligands for neuronal regeneration and functional recovery
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
TW200504036A (en) Novel lactams and uses thereof
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
WO2020106454A3 (en) Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU